SoylentNews is people
SoylentNews
One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients, first reported by CNBC.
The investment banks’ report, titled “The Genome Revolution,” asks clients the touchy question: “Is curing patients a sustainable business model?” The answer may be “no,” according to follow-up information provided.
[...] The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies... While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.
[...] Ars reached out to Goldman Sachs, which confirmed the content of the report but declined to comment.
(Score: 2) by frojack on Sunday April 15 2018, @09:12PM (1 child)
Its no secret that tig Pharma pays for drug development with high US pricing. Slightly lower EU pricing, and dirt cheap third world pricing.
This is a well known fact. The theory is that the US can afford it, and if average prices were used world wide, some places (Africa) would never be able to afford these drugs, but they would be very cheap in the US.
As for US government negotiating cost of medications...
Some people [thefiscaltimes.com] are just fine with that.
Other people, [cnn.com] not so much.
You'll be surprised at who is in which camp.
No, you are mistaken. I've always had this sig.
(Score: 0) by Anonymous Coward on Monday April 16 2018, @04:46AM
And then Trump talked to someone from the industry for five minutes and his mind was changed. Try again.